Skip to Content

Steglujan Approval History

  • FDA approved: Yes (First approved December 19, 2017)
  • Brand name: Steglujan
  • Generic name: ertugliflozin and sitagliptin
  • Dosage form: Tablets
  • Company: Merck & Co., Inc.
  • Treatment for: Diabetes, Type 2

Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.

Development History and FDA Approval Process for Steglujan

DateArticle
Dec 22, 2017Approval FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide